Maryland Oncology Hematology

Maryland Oncology Hematology is proud to welcome Dr. Paul Bannen (Olney) and Dr. Fred Smith (Chevy Chase) and their amazing staff to the MOH family. Both physicians are bringing their well-established practices into MOH, enhancing our ability to provide exceptional, community-based cancer care. We’re honored to have them join our team and look forward to continuing their legacy of compassionate, expert care.

Maryland Oncology Hematology is proud to announce the addition of a fourth LINAC machine—the Halcyon—to our Radiation Oncology program! This cutting-edge technology enhances our ability to deliver high-quality care and significantly increases patient access to treatment. The Halcyon system is designed for speed, precision, and comfort, helping us continue our commitment to compassionate, state-of-the-art cancer care. www.MarylandOncology.com

We were honored to welcome Representative Sarah Elfreth to our Annapolis office at Maryland Oncology Hematology! Her visit highlighted the power of community-based cancer care and the importance of delivering cutting-edge treatment close to home. From advanced technologies to compassionate support, we're proud to be setting the standard for oncology and hematology care in Maryland. Thank you, Representative Elfreth, for your commitment to accessible, high-quality healthcare! 💙 https://lnkd.in/eFMAmEE

Change Makers: On May 20, Maryland Oncology Hematology (MOH) attended a bill signing ceremony at the Maryland State Capitol. During the ceremony, Maryland Governor Wes Moore signed HB 1243 and SB 975 into law, which will permit cancer patients to access specialty drugs from community oncology practices and limit interference from pharmacy benefit managers (PBMs).    The bill signing culminates years of advocacy from physicians at MOH, who have worked closely with The US Oncology Network’s government relations team to hold meetings with lawmakers and provide testimony in front of key committees. This spring, Dr. Kash Firozvi testified in support of the bill, describing the benefits of medically integrated dispensing for patients, including enhanced communication between patient and provider, improved adherence, reduced drug waste, and lower costs. “Patients deserve the freedom to choose their providers and make decisions that align with their best interests,” Dr. Firozvi said. https://lnkd.in/eJFKzjB

We are excited to welcome Dr. Nadia Ashai to Maryland Oncology Hematology. Dr. Ashai is now seeing patients in Columbia and Eldersburg. Dr. Ashai is a fellowship-trained, double-board-certified medical oncologist and hematologist. She earned her medical degree from the University of Maryland School of Medicine, followed by residency training at the University of Maryland Medical Center. She then completed a fellowship in oncology at the Albert Einstein College of Medicine, Montefiore Medical Center. Dr. Ashai treats all types of hematologic and oncologic conditions, with a special interest in breast cancer care and prevention. Dr. Ashai was a member of the Breast Leadership Program at BayCare St. Joseph’s Hospital in Tampa, FL. She was on faculty at Georgetown University’s Lombardi Cancer Center where she practiced breast oncology and served as principal investigator for breast cancer treatment trials. https://lnkd.in/erC8-nM4

Welcome Dr. Ari Elman to the Maryland Oncology Hematology team. Dr. Elman will be seeing patients in Columbia and Eldersburg starting Monday, 1/6. Dr. Elman is a board-certified medical oncologist and hematologist. He earned his medical degree from the University of Maryland School of Medicine before completing a residency in internal medicine at Temple University Hospital. He went on to serve as chief resident and academic hospitalist at Lankenau Medical Center. In 2016, Dr. Elman completed his fellowship training in hematology and oncology at the University of Maryland Marlene and Stewart Greenebaum Cancer Center. During his fellowship, Dr. Elman served as a clinical instructor at the University of Maryland School of Medicine, mediating several oncology small group sessions relating to clinical oncology and pharmacology. He was also recognized with the Award for Bravery and Exceptional Service to the Patients of the University of Maryland Medical Center. https://lnkd.in/e7JhSUVc

Maryland Oncology Hematology: Leading the Way in Innovative Cancer Treatment We are thrilled to announce that Maryland Oncology Hematology is the first facility in the Maryland/DC region to receive certification for administering treatment with Optune Lua®. We extend our congratulations to Dr. Mohit Narang, the first physician in the area to earn this certification. Optune Lua® represents a significant advancement in cancer treatment. This portable device utilizes Tumor Treating Fields (TTFields) to exert physical forces on the electrically charged components of dividing cancer cells, ultimately leading to cell death. This cutting-edge technology underscores our commitment to providing the most advanced care options to our patients. As we continue to embrace advancements in cancer care, we remain steadfast in our mission to deliver innovative and effective treatments to our community. Together, we strive to bring hope and improved outcomes to those affected by cancer. https://lnkd.in/eFMAmEE